1. Home
  2. PLXS vs DNTH Comparison

PLXS vs DNTH Comparison

Compare PLXS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plexus Corp.

PLXS

Plexus Corp.

N/A

Current Price

$270.27

Market Cap

7.2B

Sector

Technology

ML Signal

N/A

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

N/A

Current Price

$88.32

Market Cap

5.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLXS
DNTH
Founded
1979
2015
Country
United States
United States
Employees
20000
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
5.9B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
PLXS
DNTH
Price
$270.27
$88.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
16
Target Price
★ $304.60
$140.80
AVG Volume (30 Days)
150.8K
★ 660.0K
Earning Date
10-21-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 56.11
N/A
EPS
★ 4.90
N/A
Revenue
N/A
★ $2,036,000.00
Revenue This Year
$21.42
N/A
Revenue Next Year
$14.96
N/A
P/E Ratio
$53.30
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$132.03
$32.28
52 Week High
$307.06
$117.88

Technical Indicators

Market Signals
Indicator
PLXS
DNTH
Relative Strength Index (RSI) 56.95 35.61
Support Level $234.17 $89.21
Resistance Level $297.13 $91.04
Average True Range (ATR) 6.33 4.60
MACD 1.79 -1.13
Stochastic Oscillator 75.43 23.83

Price Performance

Historical Comparison
PLXS
DNTH

About PLXS Plexus Corp.

Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: